<p>Infinimmune’s founding team are tool builders who design from first principles and have broad expertise across immunology, single cell technologies, protein engineering, computational biology, and genome assembly.Transforming human antibodies into drugs.</p>

Infinimmune’s founding team are tool builders who design from first principles and have broad expertise across immunology, single cell technologies, protein engineering, computational biology, and genome assembly.Transforming human antibodies into drugs.

TechBio Founders #14 : Transforming human antibodies into drugs with Wyatt McDonnell, CEO Infinimmune

#TechBio is changing the world and the world needs to know more about it and the most disruptive companies who want to enable humanity to face up to its next challenges as a species, from fighting genetically transmitted diseases and pandemics to preventing ageing and climate change. In this podcast, we are featuring founders, investors, university professor or tech advisers sharing with us their unique view on the challenges and opportunities behind the Bioeconomy. This podcast is produced by Next Sequence, a venture capital fund focused on supporting globally the #TechBio ecosystem, from founders to investors.

Share TechBio Founders #14 : Transforming human antibodies into drugs with Wyatt McDonnell, CEO Infinimmune

Sign up to save your podcasts

TechBio Founders #14 : Transforming human antibodies into drugs with Wyatt McDonnell, CEO Infinimmune

TechBio Founders #14 : Transforming human antibodies into drugs with Wyatt McDonnell, CEO Infinimmune